Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-10T10:38:12.678Z Has data issue: false hasContentIssue false
  • English
  • Français

A Rationale for Dopamine Agonists as Primary Therapy for Parkinson’s Disease

Published online by Cambridge University Press:  18 September 2015

C.W. Olanow
C.W. Olanow*
Affiliation:
Department of Neurology and Pharmacology, University of South Florida, Tampa, Florida
*
4 Columbia Drive #410, Tampa, Florida, U.S.A. 33606
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Levodopa is the most potent symptomatic treatment for Parkinson’s disease but adverse reactions are common and the initial response is not maintained. Further there is recent evidence that suggests that free radicals generated from the oxidative metabolism of dopamine may contribute to the pathogenesis of Parkinson’s disease. This raises the possibility that levodopa therapy by way of its conversion to dopamine may promote free radical formation and accelerate the rate of neuronal damage. Levodopa sparing strategies designed to minimize the cumulative levodopa dosage employed over the course of the disease seem a rational way to treat Parkinson patients in face of current information. Such a strategy would include the use of dopamine agonists as primary symptomatic therapy, the introduction of levodopa as an adjunct when dopamine agonists can no longer sufficiently provide satisfactory clinical control and the use of the lowest dose of levodopa that will provide satisfactory clinical control. In this way symptomatic control is not compromised on theoretical grounds, but the cumulative levodopa dose is minimized in an effort to reduce the likelihood of free radical formation with their potential adverse consequences on disease progression.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 19 , Issue S1: 3rd Canadian Conference on Neurodegenerative Diseases , February 1992 , pp. 108 - 112
Copyright
Copyright © Canadian Neurological Sciences Federation 1992

References

1.Calne, DB, Teychenne, PF, Clavepia, LE, et al. Bromocriptine in parkinsonism. Br Med J 1974; 4: 442–444.CrossRefGoogle ScholarPubMed
2.Fahn, S, Cote, LJ, Snider, SR, et al. The role of bromocriptine in the treatment of parkinsonism. Neurology 1979; 29: 1077–1083.CrossRefGoogle ScholarPubMed
3.Lieberman, AN, Kupersmith, M, Gopinathan, G, et al. Bromocriptine in Parkinson’s disease: further studies. Neurology 1979; 29: 363–369.CrossRefGoogle ScholarPubMed
4.Rinne, UK.Combined bromocriptine-levodopa therapy early in Parkinson’s disease. Neurology 1985; 35: 1196–1198.CrossRefGoogle ScholarPubMed
5.Rinne, UK.Early combination of bromocriptine and levodopa in the treatment of Parkinson’s disease: a five year follow-up. Neurology 1987; 37: 826–828.CrossRefGoogle Scholar
6.Olanow, CW, Alberts, MJ.A randomized blinded study of low-dose bromocriptine versus low dose carbidopa/levodopa in untreated Parkinson’s patients. In: Fahn, S, Marsden, D.Jenner, P.Teychenne, P, eds. Recent Developments in Parkinson’s Disease. New York: Raven Press, 1985: 315–321.Google Scholar
7.Olanow, CW.Oxidation reactions in Parkinson’s disease. Neurology 1990; 40: 32–37.Google ScholarPubMed
8.Halliwell, B, Gutteridge, JMC.Oxygen toxicity, oxygen radicals. transition metals and disease. J Biochem 1984; 219(1): 1–14.CrossRefGoogle ScholarPubMed
9.Minotti, G, Aust, D.The requirement for iron (III) in the initiation of lipid peroxidation by iron (II) and hydrogen peroxide. J Biol Chem 1987; 262: 1098–1104.CrossRefGoogle ScholarPubMed
10.Gutteridge, JMC, Richmond, R, Halliwell B. Inhibition of the iron-catalysed formation of hydroxy! radicals from superoxide and of lipid peroxidation by desferaioxamine. J Biochem 1979; 184: 469–472.CrossRefGoogle Scholar
11.Braughler, JM, Duncan, LA, Chase, RL.The involvement of iron in lipid peroxidation: importance of ferric to ferrous ratio in initiation. J Biol Chem 1986; 261: 10282–10289.CrossRefGoogle ScholarPubMed
12.Mello-Filho, AC, Meneghini, R.In vivo formation of single-strand breaks in DNA by hydrogen peroxide is mediated by Haber-Weiss reaction. Biochim Biophys Acta 1984; 781: 56–63.Google ScholarPubMed
13.Hallgren, B, Sourander, P.The effect of age on the nonhemin iron in the human brain. J Neurochem 1958: 3: 41–51.CrossRefGoogle Scholar
14.Floyd, RA, Zaleska, M, Harmon, HJ.Possible involvement of iron in oxygen free radicals in aspects of aging in brain. In: Armstrong, D, et al., eds. Free Radicals in Molecular Biology: Aging and Disease. New York: Raven Press, 1984: 143–161.Google Scholar
15.Earle, KM.Studies on Parkinson’s disease including x-ray, fluorescent spectroscopy of formalin-fixed brain tissue. J Neuropathol Exp Neurol 1968; 27: 1–14.CrossRefGoogle ScholarPubMed
16.Dexter, DT.Wells, RF, Lees, AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 1989; 52 (6): 1830–1836.CrossRefGoogle ScholarPubMed
17.Sofic, E, Riederer, P, Heinsen, H, et al. Increased iron (III) in total iron content in post-mortem substantia nigra of parkinsonian brain. J Neural Transm 1988; 74: 199–205.CrossRefGoogle ScholarPubMed
18.Olanow, CW, Drayer, B.Brain iron: MRI studies in Parkinson’s syndrome. In: Fahn, S, Marsden, D, Calne, D, Goldstein, M, eds. Recent Developments in Parkinson’s disease. Florum Park, NJ: MacMillan Health Care, 1987: 135–143.Google Scholar
19.Dexter, DD, Carayon, A, Vidailha, TM, et al. Decreased ferritin levels in brain in Parkinson’s disease. J Neurochem 1990; 55: 16–20.CrossRefGoogle ScholarPubMed
20.Perry, TL, Yong VW. Idiopathic Parkinson’s disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 1986; 67: 269–274.CrossRefGoogle ScholarPubMed
21.Riederer, P, Sofic, E, Rausch, WD, et al. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem 1989; 52: 515–520.CrossRefGoogle ScholarPubMed
22.Ambani, LM, VanWoert, MH, Murphy, S.Brain peroxidase and catalase in Parkinson’s disease. Arch Neurol 1975; 32: 114–118.CrossRefGoogle Scholar
23.Schapira, AHV, Cooper, JM, Dexter, D, et al. Mitochondrial complex I deficiency in Parkinson’s disease. Lancet (letter 1989; i: 1269.CrossRefGoogle Scholar
24.Mizuno, Y, Ohta, S, Tanara, M, et al. Deficiencies in complex I sub-units of the respiration chain in Parkinson’s disease. Biochem Biophys Res Commun 1989; 163:1450–1455.CrossRefGoogle Scholar
25.Dexter, DT, Carter, CJ, Wells, RF, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 1989; 52: 381–389.CrossRefGoogle ScholarPubMed
26.Halliwell, B.Oxygen radicals in human disease. Ann Intern Med 1987; 107:526–530.Google Scholar
27.Sengstock, GJ, Olanow, CW, Dunn, AJ, et al. Iron induces degeneration of substantia nigra neurons. Movement Disorders 1991; 6(3): 272.Google Scholar
28.The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364–1371.CrossRefGoogle Scholar
29.Tetrud, JW, Langston, JW.The effect of deprenyl (Selegiline) on the natural history of Parkinson’s disease. Science 1989; 245: 519–522.CrossRefGoogle ScholarPubMed
30.Spina, MB, Cohen, G.Exposure of striatal synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharmacol Exp Ther 1988; 247: 502–507.Google ScholarPubMed
31.Streece-Collier, K, Collier, TJ, Sladek, CD, et al. Chronic L-DOPA treatment decreases the viability of grafted and cultured embryonic rat mesencephalon dopamine neurons. Soc Neurosci Abstr. 1989; 15: 1354.Google Scholar
32.Clemens, JA, Phebus, LA.Dopamine depletion protects striatal neurons from ischemia-induced cell death. Life Sci 1988; 43: 707–713.CrossRefGoogle Scholar
33.Hefti, F, Melamed, E, Bhawan, J, et al. Long-term administration of L-dopa does not damage dopaminergic neurons in the mouse. Neurology 1981; 31: 1194–1195.CrossRefGoogle Scholar
34.Perry, TL, Yong, VW, Ito, M, et al. Nigrostriatal dopaminergic neurons remained undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984; 43: 990–993.CrossRefGoogle ScholarPubMed
35.Quinn, N, Parkes, JD, Janota, I, Marsden, CD.Preservation of substantia nigra and locus coeruleus in a patient receiving levodopa (2 mg) plus decarboxylase inhibitor over a four-year period. Movement Disorders 1986; 1: 65–68.CrossRefGoogle Scholar
36.Hoehn, MM.Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1983; 19: 253–264.Google Scholar
37.Markham, CH, Diamond, SG.Long-term follow-up of early dopa treatment. Ann Neurol 1986; 19: 365–372.CrossRefGoogle ScholarPubMed
38.Rajput, AH, Stern, W, Laverty, WH.Chronic low-dose levodopa therapy in Parkinson’s disease: an argument for delaying levodopa therapy. Neurology 1984; 34: 991–996.CrossRefGoogle ScholarPubMed
39.Fahn, S, Bressman, SB.Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984; 11:200–206.CrossRefGoogle ScholarPubMed
40.Cedarbaum, JM, Gandy, SE, McDowell, FH.Early initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesia or dementia in Parkinson’s disease. Neurology 1991; 41: 622–629.CrossRefGoogle ScholarPubMed
41.Mouradian, MM, Chase TN. Hypothesis: central mechanisms and levodopa response fluctuations in Parkinson’s disease. Clin Neuropharmacol 1988; 11: 378–385.CrossRefGoogle Scholar
42.Mouradian, MM, Juncos, JL, Fabbrini, G, et al. Motor fluctuation in Parkinson’s disease: central pathophysiological mechanisms, Part II. Ann Neurol 1988; 24: 372–378.CrossRefGoogle ScholarPubMed
43.Juncos, JL, Engber, TM, Rasiman, R, et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 1989; 25: 473–478.CrossRefGoogle ScholarPubMed
44.Bedard, PJ, Dipaolo, T, Falardeau, T, et al. Chronic treatment with L-dopa but not bromocriptine induces dyskinesia in MPTP parkinsonian monkeys. Correlation with (3H) spiperone binding. Brain Res 1986; 379: 294–299.CrossRefGoogle Scholar
45.Olanow, CW, Gauger, LL, Cedarbaum, J.Temporal relationships between plasma and CSF pharmacokinetics of levodopa and clinical effect in Parkinson’s disease. Ann Neurol 1991; 29: 556–559.CrossRefGoogle Scholar
46.Cedarbaum, JM, Olanow, CW.Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson’s disease. Neurology 1991; 41: 1567–1570.CrossRefGoogle ScholarPubMed
47.Felten, DL, Felten, SY, Fuller, TW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer 344 rats. Neurobiol Aging (in press).Google Scholar
48.Olanow, CW, Alberts, MJ.Low-dose bromocriptine in previously untreated Parkinson patients. In: Fahn, S, Marsden, CD, Jenner, P, eds. Recent Developments in Parkinson’s disease. New York: Raven Press, 1986: 273–278.Google Scholar
49.Olanow, CW, Alberts, MJ.A double-blind controlled study of pergolide mesylate in the treatment of Parkinson’s disease. Clin Neuropharmol 1987; 10: 178–185.CrossRefGoogle ScholarPubMed